State Street Corp Summit Therapeutics Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, State Street Corp holds 8,114,230 shares of SMMT stock, worth $63.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,114,230

Previous 2,456,168 230.36%

Holding current value

$63.3 Million

Previous $6.41 Million 424.06%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $14.4 Million - $28.7 Million	5,658,062 Added 230.36%	8,114,230 $33.6 Million
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.83 $316,630 - $536,565	189,599 Added 8.37%	2,456,168 $6.41 Million
Q3 2023 Nov 14, 2023	BUY	$1.54 - $2.42 $19,394 - $30,477	12,594 Added 0.56%	2,266,569 $4.24 Million
Q2 2023 Aug 14, 2023	BUY	$1.32 - $2.81 $2.81 Million - $5.99 Million	2,131,675 Added 1742.99%	2,253,975 $5.66 Million
Q1 2023 May 15, 2023	BUY	$1.38 - $5.41 $47,471 - $186,104	34,400 Added 39.14%	122,300 $214,000

Q4 2022 Feb 14, 2023	BUY	$0.68 - $5.31 $59,772 - $466,748	87,900 New	87,900 $373,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.38 $288,328 - $745,894	-313,401 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.0 - $3.45 $47,426 - $81,809	-23,713 Reduced 7.03%	313,401 $768,000
Q4 2021 Feb 14, 2022	BUY	$2.45 - $5.64 $2,244 - $5,166	916 Added 0.27%	337,114 $907,000
Q3 2021 Nov 15, 2021	BUY	$4.83 - $8.27 $383,975 - $657,448	79,498 Added 30.97%	336,198 $1.68 Million
Q2 2021 Aug 16, 2021	BUY	$5.15 - $8.46 $1.32 Million - $2.17 Million	256,700 New	256,700 $1.92 Million

Others Institutions Holding SMMT

# of Institutions

107

Shares Held

41.3M

Call Options Held

103K

Put Options Held

29.9K

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $1.57B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Summit Therapeutics Inc. Transaction History